Thomson Reuters

Newport Horizon GlobalTM is the critical product targeting and global business development system from Thomson Reuters, the industry authority on the global generics market.

Created specifically for generic pharmaceutical companies and strategic API manufacturers, it can help you to identify and evaluate product opportunities worldwide, ensuring you'll be first to find the generic product and niche opportunity, first to make the deal, and first to get to market.

Powerful integrated global information with unique analysis.

With Newport Horizon Global, you can:

• Recognize critical patent, exclusivity and regulatory issues with candidate products.
• Discover early, exclusive sources of API supply.
• Profile competitors, business partners, and candidate products for acquisition, alliances, licensing, or supply and manufacturing.
• Track and monitor the launch, API development and patenting activities of competitors worldwide.
• Evaluate candidate products against the earliest competitive intelligence.
• Evaluate new product development opportunities in any market, worldwide.
• Identify niche opportunities that match your strategic needs and unique research, sales or marketing strengths.
• Adjust your research timing, priorities and resources based on active competitive intelligence monitoring.

Why choose Newport Horizon Global?

• Unique strategic intelligence. Newport Horizon Global incorporates the unique strategic intelligence and powerful competitive analysis that is only available from Thomson Scientific. It integrates intelligence on more than 40,000 launched products containing over 10,000 different active ingredients and over 20,000 corporate groups.
• Sophisticated targeting capabilities. Newport Horizon Global can help you to profile promising new partner companies, identify global product licensing and acquisition opportunities, and secure early, exclusive sources of API supply.
• Test and explore new business strategies. Newport Horizon Global can help you to recognize potential barriers to market entry, and plan your development pipeline effectively. With the industry's most sophisticated product targeting capabilities, it can significantly enhance your competitive edge.

• Sales, launch, approval and regulatory data for more than 40,000 launched products.
• Profiles of more than 20,000 companies and corporate groups, including subsidiary, launch, approvals, regulatory filings and APIs manufactured.
• Detailed manufacturing capabilities for an increasing number of sites.
• Alerting on key changes in products and companies, including new regulatory filings and approvals.
• Unique, early API manufacturing intelligence.
• Worldwide patent families and individual patents for more than 90 countries.
• Comprehensive Supplementary Protection Certificate (SPC) data for Europe.
• Projected loss of exclusivity dates for US and EEC markets.
• Sales figures by molecule and by dosage form for major world market regions, including two-year sales history.
• Current retail and hospital dose pack pricing for each dose form and strength of all products in more than 65 countries.
• Paragraph IV patent challenges commentaries, including company identities, FTF and status of litigation for more than 190 products.
• Product launch and first market authorization data, country-by-country.
• Orange book approved dose forms, US Drug Master Files, EU Certificates of Suitability and FDA warning letters and issues.
• Labeling and prescribing data for more than 1,800 unique products.
• Chemical structure diagram and details of alternative structures for thousands of products.
• Powerful indexing and searching of products according to FDA approved indication and technology class.